Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - AMAG PHARMACEUTICALS, INC. | ex312201610-k.htm |
| EX-32.2 - EXHIBIT 32.2 - AMAG PHARMACEUTICALS, INC. | ex322201610-k.htm |
| EX-32.1 - EXHIBIT 32.1 - AMAG PHARMACEUTICALS, INC. | ex321201610-k.htm |
| EX-31.1 - EXHIBIT 31.1 - AMAG PHARMACEUTICALS, INC. | ex311201610-k.htm |
| EX-21.1 - EXHIBIT 21.1 - AMAG PHARMACEUTICALS, INC. | ex211201610-k.htm |
| EX-10.34 - EXHIBIT 10.34 - AMAG PHARMACEUTICALS, INC. | ex1034amag-pfizerlicenseag.htm |
| 10-K - 10-K - AMAG PHARMACEUTICALS, INC. | amag201610-k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Forms S‑3 (File Nos. 333‑202009 and 333-202252) and Forms S‑8 (File Nos. 333‑82292, 333‑131656, 333‑148682, 333‑159938, 333‑168786, 333-182821, 333‑190435, 333‑197873, 333-203924 and 333-211277) of AMAG Pharmaceuticals, Inc. of our report dated February 17, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP | |
Boston, Massachusetts | |
February 17, 2017 | |